Visual Abstract

Visual Abstract
Visual Abstract.
View largeDownload slide
Keywords:
Metabolic acidosis, Muscle mass, Lean body mass, Renal function, Chronic kidney disease

Background: Treatment of metabolic acidosis to target the higher serum bicarbonate level than guideline recommendation may downregulate muscle protein degradation and improve renal function among chronic kidney disease (CKD) patients. We conducted a study to test the effects of increased serum bicarbonate level on muscle parameters, nutrition, and renal function in pre-dialysis CKD patients. Methods: This was a randomized, controlled study. CKD stage 3–4 patients with serum HCO3– <22 mEq/L were randomized to either receive oral sodium bicarbonate with high target bicarbonate level of 25 ± 1 or standard level of 22 ± 1 mEq/L as control group using protocol-based titration of dosage adjustment. The changes of muscle mass measured by bioelectrical impedance analysis (BIA), muscle strength by hand grip dynamometer, estimated glomerular filtration rate (eGFR) using CKD-Epidemiology Collaboration equation, nutritional markers, and muscle-related biomarkers were determined. Data at baseline and after 4 months of sodium bicarbonate supplementation were compared between groups using Student t test or chi-square test as appropriate. Results: Forty-two patients completed the study (n = 21 per group). The mean age and eGFR were 61.2 ± 9.8 years and 32.4 ± 14.1 mL/min respectively. Serum bicarbonate levels at baseline were 21.0 ± 2.1 mEq/L. Baseline data including sex, diabetes, serum bicarbonate level, creatinine, and blood pressure were similar. After 4 months of treatment, the average serum bicarbonate levels in both groups were 24.0 ± 1.4 and 20.7 ± 2.3 mEq/L (p < 0.001). Both BIA-derived total-body muscle mass and appendicular lean balance were increased at 4 months in the higher bicarbonate group (26.0 ± 5.3 to 26.7 ± 5.5 kg, p = 0.04 and 19.8 ± 4.1 to 20.7 ± 4.4 kg, p = 0.06, respectively) despite comparable body weight and protein intake. Patients in the high bicarbonate group had a significant reduction of plasma myostatin levels, a surrogate of muscle degradation, at the study exit after adjusting for baseline values (–3,137.8; 95% CI –6,235.3 to –40.4 pg/mL, p= 0.04), but unaltered insulin-like growth factor-1 level, as the mediator of muscle cell growth, (141 [106–156] to 110 [87–144] ng/mL, p = 0.13) compared to the control group. Muscle strength, eGFR as well as serum prealbumin were not significantly different between 2 groups (p > 0.05). Neither worsening hypertension nor congestive heart failure was found throughout the study. Conclusion: Bicarbonate supplementation to achieve the serum level ∼24 mEq/L demonstrates better muscle mass preservation in patients with pre-dialysis CKD. The impact of alkaline therapy on renal function may require a longer period of study.

Keywords:
Metabolic acidosis, Muscle mass, Lean body mass, Renal function, Chronic kidney disease
1.
Raphael KL, Zhang Y, Ying J, Greene T. Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease.
Nephrology (Carlton)
. 2014 Oct;19(10):648–54.
2.
Driver TH, Shlipak MG, Katz R, Goldenstein L, Sarnak MJ, Hoofnagle AN, et al. Low serum bicarbonate and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA).
Am J Kidney Dis
. 2014 Oct;64(4):534–41.
3.
Raphael KL, Wei G, Baird BC, Greene T, Beddhu S. Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans.
Kidney Int
. 2011 Feb;79(3):356–62.
4.
Shah SN, Abramowitz M, Hostetter TH, Melamed ML. Serum bicarbonate levels and the progression of kidney disease: a cohort study.
Am J Kidney Dis
. 2009 Aug;54(2):270–7.
5.
Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Wehbe E, Raina R, et al. Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease.
Clin J Am Soc Nephrol
. 2011 Oct;6(10):2395–402.
6.
Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD.
Nephrol Dial Transplant
. 2009 Apr;24(4):1232–7.
7.
de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status.
J Am Soc Nephrol
. 2009 Sep;20(9):2075–84.
8.
Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.
Kidney Int
. 2010 Aug;78(3):303–9.
9.
Dobre M, Rahman M, Hostetter TH. Current status of bicarbonate in CKD.
J Am Soc Nephrol
. 2015 Mar;26(3):515–23.
10.
Wilson FP, Xie D, Anderson AH, Leonard MB, Reese PP, Delafontaine P, et al.; CRIC Study Investigators. Urinary creatinine excretion, bioelectrical impedance analysis, and clinical outcomes in patients with CKD: the CRIC study.
Clin J Am Soc Nephrol
. 2014 Dec;9(12):2095–103.
11.
Chang YT, Wu HL, Guo HR, Cheng YY, Tseng CC, Wang MC, et al. Handgrip strength is an independent predictor of renal outcomes in patients with chronic kidney diseases.
Nephrol Dial Transplant
. 2011 Nov;26(11):3588–95.
12.
Zhang L, Rajan V, Lin E, Hu Z, Han HQ, Zhou X, et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease.
FASEB J
. 2011 May;25(5):1653–63.
13.
Zhang L, Wang XH, Wang H, Du J, Mitch WE. Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy.
J Am Soc Nephrol
. 2010 Mar;21(3):419–27.
14.
Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling.
Endocrinology
. 2006 Sep;147(9):4160–8.
15.
Ballmer PE, McNurlan MA, Hulter HN, Anderson SE, Garlick PJ, Krapf R. Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans.
J Clin Invest
. 1995 Jan;95(1):39–45.
16.
Chiu YW, Kopple JD, Mehrotra R. Correction of metabolic acidosis to ameliorate wasting in chronic kidney disease: goals and strategies.
Semin Nephrol
. 2009 Jan;29(1):67–74.
17.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
Kidney Int Suppl
. 2013;3:1–150.
18.
Dobre M, Yang W, Chen J, Drawz P, Hamm LL, Horwitz E, et al.; CRIC Investigators. Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study.
Am J Kidney Dis
. 2013 Oct;62(4):670–8.
19.
Dobre M, Yang W, Pan Q, Appel L, Bellovich K, Chen J, et al.; CRIC Study Investigators. Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study.
J Am Heart Assoc
. 2015 Apr;4(4):e001599.
20.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate.
Ann Intern Med
. 2009 May;150(9):604–12.
21.
Kraut JA, Madias NE. Metabolic Acidosis of CKD: an Update.
Am J Kidney Dis
. 2016 Feb;67(2):307–17.
22.
Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure.
Kidney Int
. 1985 Jan;27(1):58–65.
23.
Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia.
J Am Med Dir Assoc
. 2014 Feb;15(2):95–101.
24.
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al.; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis.
Age Ageing
. 2019 Jan;48(1):16–31.
25.
Dubey AK, Sahoo J, Vairappan B, Haridasan S, Parameswaran S, Priyamvada PS. Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial.
Nephrol Dial Transplant
. 2018, Epub ahead of print.
26.
Jeong J, Kwon SK, Kim HY. Effect of bicarbonate supplementation on renal function and nutritional indices in predialysis advanced chronic kidney disease.
Electrolyte Blood Press
. 2014 Dec;12(2):80–7.
27.
Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease.
Nat Rev Nephrol
. 2014 Sep;10(9):504–16.
28.
Kuzyarova A, Gasanov M, Batyushin M, Golubeva O, Najeva M. The role of myostatin and protein kinase-B in the development of protein-energy deficiency in patients with end-stage renal disease on hemodialysis.
Georgian Med News
. 2019 Apr;(289):47–50.
29.
Bellasi A, Di Micco L, Santoro D, Marzocco S, De Simone E, Cozzolino M, et al.; UBI study investigators. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease.
BMC Nephrol
. 2016 Oct;17(1):158.
30.
Abramowitz MK, Melamed ML, Bauer C, Raff AC, Hostetter TH. Effects of oral sodium bicarbonate in patients with CKD.
Clin J Am Soc Nephrol
. 2013 May;8(5):714–20.
31.
Vallet M, Metzger M, Haymann JP, Flamant M, Gauci C, Thervet E, et al.; NephroTest Cohort Study group. Urinary ammonia and long-term outcomes in chronic kidney disease.
Kidney Int
. 2015 Jul;88(1):137–45.
32.
Raphael KL. Metabolic Acidosis and Subclinical Metabolic Acidosis in CKD.
J Am Soc Nephrol
. 2018 Feb;29(2):376–82.
33.
Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, et al. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR.
Kidney Int
. 2010 Apr;77(7):617–23.
34.
Goraya N, Simoni J, Jo CH, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate.
Kidney Int
. 2014 Nov;86(5):1031–8.
35.
Chen W, Levy DS, Abramowitz MK. Acid Base Balance and Progression of Kidney Disease.
Semin Nephrol
. 2019 Jul;39(4):406–17.
36.
Navaneethan SD, Shao J, Buysse J, Bushinsky DA. Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-Analysis.
Clin J Am Soc Nephrol
. 2019 Jul;14(7):1011–20.
37.
Dellière S, Cynober L. Is transthyretin a good marker of nutritional status?
Clin Nutr
. 2017 Apr;36(2):364–70.
38.
Luft FC, Steinberg H, Ganten U, Meyer D, Gless KH, Lang RE, et al. Effect of sodium chloride and sodium bicarbonate on blood pressure in stroke-prone spontaneously hypertensive rats.
Clin Sci (Lond)
. 1988 Jun;74(6):577–85.
39.
Weinberger MH. Sodium chloride and blood pressure.
N Engl J Med
. 1987 Oct;317(17):1084–6.
40.
Ling CH, de Craen AJ, Slagboom PE, Gunn DA, Stokkel MP, Westendorp RG, et al. Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population.
Clin Nutr
. 2011 Oct;30(5):610–5.
41.
Pham AQ, Xu LH, Moe OW. Drug-Induced Metabolic Acidosis.
F1000Res
. 2015;4:pii:F1000.
42.
DuBose TD Jr. Urine Ammonium and Preclinical Acidosis in CKD.
J Am Soc Nephrol
. 2017 Aug;28(8):2258–60.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.